SpyGlass Pharma, Inc.
Close on Oct 19, 2026
- Market cap
- $822.61M
- P/E (TTM)
- –
- Dividend yield
- –
About SpyGlass Pharma
Surgical & Medical Instruments & Apparatus, SIC 3841
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company focused on developing long-acting, sustained-release drug delivery therapies for chronic ocular conditions. Its primary product candidate in development is the Bimatoprost Drug Pad-IOL System, which combines proprietary drug pads with an intraocular lens to deliver bimatoprost directly during cataract surgery. This system is designed to treat patients with open-angle glaucoma or ocular hypertension by reducing elevated intraocular pressure. The company is also developing a standalone, non-lens, ring-shaped implant to provide sustained bimatoprost delivery for pseudophakic glaucoma patients.
The company operates in a single reporting segment dedicated to the development of its ophthalmic drug delivery technologies. It conducts its clinical operations across 45 trial sites located within the United States. SpyGlass Pharma, Inc. maintains its principal executive offices and headquarters in Aliso Viejo, California.
Summary of the business section of SpyGlass Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SpyGlass Pharma, Inc.
- Headquarters
- Irvine, CA
- Address
- 15326 Alton Parkway 92618
- Phone
- (949) 284-6904
- Website
- spyglasspharma.com
- Employees
- 65, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Costa Mesa, CA
Stock & identifiers
- Ticker
- SGP
- Exchange
- Nasdaq
- IPO date
- Feb 6, 2026
- Shares outstanding
- 33M, Jul 29, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1778922
- CUSIP
- 85220G109
- ISIN
- US85220G1094
- EIN
- 83-3044245
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Patrick H. Mooney | Chief Executive Officer, Director | 183,153 |
| Malik Y. Kahook | See remarks, Director | 873,978 |
| Chetan Pratap Pujara | Chief R&D Officer | – |
| James Robert Dennewill Jr. | Chief Operating Officer | 96,022 |
| Jean-Frederic Viret | Chief Financial Officer | – |
| Ali Behbahani | Director | 2,574,230 |
| Capital Healthcare Fund LP RA | Director | 2,524,473 |
| Rajeev M. Shah | Director | – |
| RA Capital Nexus Fund III, L.P. | Director | – |
| Peter Kolchinsky | Director | – |
| Ra Capital Management, L.P. | Director | – |
| Geoffrey B. Pardo | Director | 2,187,513 |
| Kirk G. Nielsen | Director | 3,310,619 |
| Bilal Arshad Khan | Director | 276,877 |
| Elizabeth G. O'Farrell | Director | – |
| Zachary Scheiner | Director | – |
| Habib J. Dable | Director | – |
| Michael Dybbs | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 6, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 5, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jan 5, 2021 | Name change | Name changed from SpyGlass Ophthalmics, Inc. to SpyGlassPharma, Inc. |